Background Lung adenocarcinoma (LUAD) is the leading histological subtype of lung
cancer worldwide, causing high mortality each year. The tumor immune cell infiltration (ICI) …

Background: Although immunotherapy with checkpoint inhibitors is changing the face of
lung adenocarcinoma (LUAD) treatments, only limited patients could benefit from it …

Background Lung adenocarcinoma (LUAD) as a frequent type of lung cancer has a 5-year
overall survival rate of lower than 20% among patients with advanced lung cancer. This …

Accumulated evidence shows that tumor microenvironment plays crucial roles in predicting
clinical outcomes of lung adenocarcinoma (LUAD). The current study aimed to identify some …

The high risk of postoperative mortality in lung adenocarcinoma (LUAD) patients is
principally driven by cancer recurrence and low response rates to adjuvant treatment. Here …

Lung cancer is a serious malignancy, and lung adenocarcinoma (LUAD) is the most
common pathological subtype. Immune-related factors play an important role in lymph node …

The existence of tumor heterogeneity and complex carcinogenic mechanisms in lung
adenocarcinoma (LUAD) make the most commonly used TNM staging system unable to well …

Background Lung adenocarcinoma (LUAD) is a common malignant tumor with the highest
morbidity and mortality worldwide. The degree of tumor immune infiltration and clinical …

Background: Lung cancer, especially lung adenocarcinoma (LUAD) with high incidence,
seriously endangers human life. The immune microenvironment is one of the malignant …

Background Lung adenocarcinomas (LUAD) is the most common histological subtype of
lung cancers. Tumor immune microenvironment (TIME) is involved in tumorigeneses …